<Version>
  <xmlSource>This XML content was developed by AHRQ's contractor ECRI Institute for the National Guideline Clearinghouse (NGC).</xmlSource>
  <Section SecID="390" OrdBy="100" Name="General">
    <Field FieldID="161" OrdBy="105" ID="391" Name="Guideline Title" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_title&quot;&gt;Traditional Chinese medicine treatment guideline for primary headache disorders.&lt;/div&gt;" />
    </Field>
    <Field FieldID="97" OrdBy="110" ID="392" Name="Bibliographic Source(s)" Type="citation">
      <FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Guangdong Provincial Hospital of Chinese Medicine. Traditional Chinese medicine treatment guideline for primary headache disorders. Guangdong Sheng (China): Guangdong Provincial Hospital of Chinese Medicine; 2018 Jan 30. 5 p.  [44 references]&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" />
    </Field>
    <Field FieldID="120" OrdBy="115" ID="393" Name="Guideline Status" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;This guideline meets NGC's 2013 (revised) inclusion criteria.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
  </Section>
  <Section SecID="705" OrdBy="150" Name="NEATS Assessment">
    <Field FieldID="183" OrdBy="10" ID="706" Name="Disclosure of Guideline Funding Source" Type="picklist-one">
      <FieldValue Value="Yes" />
    </Field>
    <Field FieldID="184" OrdBy="20" ID="707" Name="Disclosure and Management of Financial Conflict of Interests" Type="picklist-one">
      <FieldValue Value="3" />
    </Field>
    <Field FieldID="185" OrdBy="30" ID="708" Name="Guideline Development Group Composition: Multidisciplinary Group" Type="picklist-one">
      <FieldValue Value="Yes" />
    </Field>
    <Field FieldID="186" OrdBy="40" ID="709" Name="Guideline Development Group Composition: Methodologist Involvement" Type="picklist-one">
      <FieldValue Value="Yes" />
    </Field>
    <Field FieldID="187" OrdBy="50" ID="710" Name="Guideline Development Group Composition: Patient and Public Perspectives" Type="picklist-one">
      <FieldValue Value="3" />
    </Field>
    <Field FieldID="188" OrdBy="60" ID="711" Name="Use of a Systematic Review of Evidence: Search Strategy" Type="picklist-one">
      <FieldValue Value="5" />
    </Field>
    <Field FieldID="189" OrdBy="70" ID="712" Name="Use of a Systematic Review of Evidence: Study Selection" Type="picklist-one">
      <FieldValue Value="5" />
    </Field>
    <Field FieldID="190" OrdBy="80" ID="713" Name="Use of a Systematic Review of Evidence: Synthesis of Evidence" Type="picklist-one">
      <FieldValue Value="4" />
    </Field>
    <Field FieldID="191" OrdBy="90" ID="714" Name="Evidence Foundations for and Rating Strength of Recommendations: Grading the Quality or Strength of Evidence" Type="picklist-one">
      <FieldValue Value="3" />
    </Field>
    <Field FieldID="192" OrdBy="100" ID="715" Name="Evidence Foundations for and Rating Strength of Recommendations: Benefits and Harms of Recommendations" Type="picklist-one">
      <FieldValue Value="3" />
    </Field>
    <Field FieldID="193" OrdBy="110" ID="716" Name="Evidence Foundations for and Rating Strength of Recommendations: Evidence Summary Supporting Recommendations" Type="picklist-one">
      <FieldValue Value="4" />
    </Field>
    <Field FieldID="194" OrdBy="120" ID="717" Name="Evidence Foundations for and Rating Strength of Recommendations: Rating the Strength of Recommendations" Type="picklist-one">
      <FieldValue Value="2" />
    </Field>
    <Field FieldID="195" OrdBy="130" ID="718" Name="Specific and Unambiguous Articulation of Recommendations" Type="picklist-one">
      <FieldValue Value="1" />
    </Field>
    <Field FieldID="196" OrdBy="140" ID="719" Name="External Review" Type="picklist-one">
      <FieldValue Value="1" />
    </Field>
    <Field FieldID="197" OrdBy="150" ID="720" Name="Updating" Type="picklist-one">
      <FieldValue Value="2" />
    </Field>
  </Section>
  <Section SecID="420" OrdBy="300" Name="Recommendations">
    <Field FieldID="151" OrdBy="310" ID="421" Name="Major Recommendations" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Definitions of the strength of recommendations (&lt;strong&gt;Strong, Weak, No clear recommendation&lt;/strong&gt;) are provided at the end of the &quot;Major Recommendations&quot; field. &lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Recommendations&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Migraine&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Acupuncture&lt;/em&gt; (Strength of recommendation: Strong; Quality of evidence: Low) &lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Tianshu capsule&lt;/em&gt; (Strength of recommendation: Weak; Quality of evidence: Low). Its active ingredients are ligusticum wallichii and rhizoma gastrodiae. &lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Chuanxiong chatiao powder&lt;/em&gt; (Strength of recommendation: Weak; Quality of evidence: Very low). Its active ingredients are ligusticum wallichii, angelica dahurica, notopterygium root, asarum sieboldii, radix sileris, schizonepeta, mint and liquorice. &lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Duliang capsule&lt;/em&gt; (Strength of recommendation: Weak; Quality of evidence: Very low). Its active ingredients are ligusticum wallichii and angelica dahurica. &lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Toutongning capsule&lt;/em&gt; (Strength of recommendation: Weak; Quality of evidence: Low). Its active ingredients are glabrous greenbrier rhizome, rhizoma gastrodiae, radix polygonum multiflorum preparata, angelica sinensis, radix sileris and medicinal scorpion. &lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Blood-letting&lt;/em&gt; (Strength of recommendation: Weak; Quality of evidence: Low) &lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Yangxueqingnao granule&lt;/em&gt; (Strength of recommendation: Weak; Quality of evidence: Low). Its active ingredients are angelica sinensis, ligusticum wallichii, white paeonia, prepared rehmannia root, uncaria, caulis spatholobi, selfheal, semen cassiae, nacre, rhizoma corydalis and asarum. &lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Tension-type Headache&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Acupuncture&lt;/em&gt; (Strength of recommendation: Strong; Quality of evidence: Moderate) &lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Tuina (Massage)&lt;/em&gt; (Strength of recommendation: Strong; Quality of evidence: Moderate) &lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Yangxueqingnao granule&lt;/em&gt; (Strength of recommendation: Weak; Quality of evidence: Very low). Its active ingredients are angelica sinensis, ligusticum wallichii, white paeonia, prepared rehmannia root, uncaria, caulis spatholobi, selfheal, semen cassiae, nacre, rhizoma corydalis and asarum. &lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Toutongning capsule&lt;/em&gt; (Strength of recommendation: Weak; Quality of evidence: Very low). Its active ingredients are glabrous greenbrier rhizome, rhizoma gastrodiae, radix polygonum multiflorum preparata, angelica sinensis, radix sileris and medicinal scorpion. &lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Acupoint injection&lt;/em&gt; (Strength of recommendation: None; Quality of evidence: Very low) &lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Cluster Headache&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Acupuncture&lt;/em&gt; (Strength of recommendation: Weak; Quality of evidence: Low) &lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Toutongning capsule&lt;/em&gt; (Strength of recommendation: Weak; Quality of evidence: Very low). Its active ingredients are glabrous greenbrier rhizome, rhizoma gastrodiae, radix polygonum multiflorum preparata, angelica sinensis, radix sileris and medicinal scorpion. &lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Tianma injection&lt;/em&gt; (Strength of recommendation: None; Quality of evidence: Very low). Its active ingredient is rhizoma gastrodiae.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Definitions&lt;/span&gt;&lt;/strong&gt; &lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Strength of Recommendation &lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;1&quot; cellpadding=&quot;3&quot; summary=&quot;Table: Strength of Recommendation&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot; scope=&quot;col&quot;&gt;Recommendation&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot; scope=&quot;col&quot;&gt;Benefits and Risks&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Strong &quot;Must do&quot;&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Benefits clearly outweigh risks&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Weak &quot;Might do&quot;&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Benefits might outweigh risks&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;No clear recommendation&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Benefits are equal to risks OR uncertain&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Weak &quot;Might do&quot;&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Risk might outweigh benefits&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Weak &quot;Must not do&quot;&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Risks clearly outweigh benefits&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="138" OrdBy="330" ID="423" Name="Clinical Algorithm(s)" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None provided&lt;/p&gt;&lt;/div&gt;" />
    </Field>
  </Section>
  <Section SecID="396" OrdBy="400" Name="Scope">
    <Field FieldID="140" OrdBy="405" ID="397" Name="Disease/Condition(s)" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Primary headache disorders (migraine, tension headache, cluster headache)&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&lt;strong&gt;Note&lt;/strong&gt;: Diagnosis of primary headache refers to the International Classification of Headache Disorders, 2nd Edition (ICHD-II).&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="103" OrdBy="410" ID="398" Name="Guideline Category" Type="picklist-many">
      <FieldValue Value="Treatment" />
    </Field>
    <Field FieldID="113" OrdBy="415" ID="399" Name="Clinical Specialty" Type="picklist-many">
      <FieldValue Value="Family Practice" />
      <FieldValue Value="Neurology" />
    </Field>
    <Field FieldID="114" OrdBy="420" ID="400" Name="Intended Users" Type="picklist-many">
      <FieldValue Value="Physicians" />
    </Field>
    <Field FieldID="129" OrdBy="425" ID="401" Name="Guideline Objective(s)" Type="text">
      <FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;To provide Traditional Chinese Medicine therapy guidelines for migraine, tension-type headache and cluster headache based on systematic reviews &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;To address the following key questions:&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Key Question 1: Is acupuncture effective for patient with migraine? &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Key Question 2: Is tianshu capsule effective for patient with migraine? &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Key Question 3: Is chuanxiong chatiao powder effective for patient with migraine? &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Key Question 4: Is duliang capsule effective for patient with migraine? &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Key Question 5: Is toutongning capsule effective for patient with migraine? &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Key Question 6: Is blood-letting effective for patient with migraine? &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Key Question 7: Is yangxueqingnao granule effective for patient with migraine? &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Key Question 8: Is acupuncture effective for patient with tension-type headache? &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Key Question 9: Is tuina effective for patient with tension-type headache? &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Key Question 10: Is yangxueqingnao granule effective for patient with tension-type headache? &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Key Question 11: Is toutongning capsule effective for patient with tension-type headache? &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Key Question 12: Is acupoint injection effective for patient with tension-type headache? &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Key Question 13: Is acupuncture effective for patient with cluster headache? &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Key Question 14: Is toutongning capsule effective for patient with cluster headache? &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Key Question 15: Is tianma injection effective for patient with cluster headache? &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" />
    </Field>
    <Field FieldID="132" OrdBy="430" ID="402" Name="Target Population" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Adults (aged &amp;ge;18 years) with headache &lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&lt;strong&gt;Note&lt;/strong&gt;: Juveniles and pregnant women are not included.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="133" OrdBy="435" ID="403" Name="Interventions and Practices Considered" Type="text">
      <FieldValue Value="&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;Acupuncture &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Chinese patent drugs&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Tianshu capsule &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Chuanxiong chatiao powder &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Duliang capsule &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Toutongning capsule &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Tianma injection &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Yangxueqingnao granule &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Acupoint injection &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Blood-letting &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Tuina  &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;" />
    </Field>
    <Field FieldID="134" OrdBy="440" ID="404" Name="Major Outcomes Considered" Type="text">
      <FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Clinical efficacy rate &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Visual analogue scale (VAS) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Headache frequency &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Headache duration &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Incidence of adverse reaction &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" />
    </Field>
  </Section>
  <Section SecID="405" OrdBy="500" Name="Methodology">
    <Field FieldID="109" OrdBy="505" ID="406" Name="Methods Used to Collect/Select the Evidence" Type="picklist-many">
      <FieldValue Value="Searches of Electronic Databases" />
    </Field>
    <Field FieldID="135" OrdBy="510" ID="407" Name="Description of Methods Used to Collect/Select the Evidence" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Search Strategy of Systematic Reviews&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Chinese Databases&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The guideline development team searched Chinese databases (China National Knowledge Infrastructure, WANFANG DATA, China Biology Medicine and VIP). They ran the search with the date restrictions of database inception through October 2015.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;English Databases&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The guideline development team searched English databases (PubMed, EMBASE, Cochrane Library and Web of Science). They ran the search with the date restrictions of database inception through December 2015. &lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Search Strategy of Original Research&lt;/span&gt;&lt;/strong&gt; &lt;/p&gt;&#xD;&#xA;&lt;p&gt;After the search of existing systematic reviews, there were still some clinical questions the guideline development group needed to answer. So, they searched the original research to develop new systematic reviews. They searched Chinese databases (China National Knowledge Infrastructure, WANFANG DATA, China Biology Medicine) and English databases (PubMed, EMBASE, Cochrane Library and Web of Science). They ran the search with the date restrictions of database inception through March 2016. Refer to the Appendix (see the &quot;Availability of Companion Documents&quot; field) for searches of different clinical questions.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Study Selection&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Two independent reviewers conducted title scans and advanced articles if either one thought them relevant. The abstract review phase was designed to identify studies reporting the effectiveness or safety of the intervention. Two investigators independently reviewed abstracts. Differences between investigators regarding the inclusion or exclusion of abstracts were resolved through consensus adjudication. Full articles underwent another independent parallel review regarding their appropriateness for inclusion. Refer to the Appendix (see the &quot;Availability of Companion Documents&quot; field) for selection criteria for systematic reviews and original studies.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="136" OrdBy="515" ID="408" Name="Number of Source Documents" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;A total of 3965 records were identified through database searching. After removing duplicates, the guideline development group included 2685 systematic reviews. After reviewing titles, abstracts, they included 96 systematic reviews. Finally, after reviewing the full text, a total of 43 systematic reviews were included.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;See Appendix 10 (see the &quot;Availability of Companion Documents&quot; field) for literature search results of original studies presented by key question.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="115" OrdBy="520" ID="409" Name="Methods Used to Assess the Quality and Strength of the Evidence" Type="picklist-choice">
      <FieldValue Value="Weighting According to a Rating Scheme (Scheme Given)" />
    </Field>
    <Field FieldID="149" OrdBy="525" ID="410" Name="Rating Scheme for the Strength of the Evidence" Type="text">
      <FieldValue Value="&lt;table border=&quot;1&quot; cellspacing=&quot;1&quot; cellpadding=&quot;3&quot; summary=&quot;Table: Strength of the Bodt of Evidence&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot; scope=&quot;col&quot;&gt;Strength of the Body of Evidence&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot; scope=&quot;col&quot;&gt;Definition&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;High&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Very confident that the true effect lies close to that of the estimate of the effect.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Moderate&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Moderately confident in the effect estimate. The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Low&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Confidence in the effect estimate is limited. The true effect may be substantially different from the estimate of the effect.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Very low&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Very little confidence in the effect estimate. The true effect is likely to be substantially different from the estimate of the effect. &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;" />
    </Field>
    <Field FieldID="116" OrdBy="530" ID="411" Name="Methods Used to Analyze the Evidence" Type="picklist-many">
      <FieldValue Value="Meta-Analysis" />
      <FieldValue Value="Review of Published Meta-Analyses" />
      <FieldValue Value="Systematic Review with Evidence Tables" />
    </Field>
    <Field FieldID="150" OrdBy="535" ID="412" Name="Description of the Methods Used to Analyze the Evidence" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Data Extraction&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Data extraction was conducted in the development of new systematic reviews. The guideline development group used standardized forms from the previous reviews as templates for data extraction and pilot tested them for the new medications and outcomes. By creating standardized forms for data extraction, they sought to maximize consistency in identifying all pertinent data available for synthesis.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;For all articles, the reviewers extracted information on the general study characteristics (e.g., title, study site, source of funding, study design, study period); study participants (e.g., age, gender, inclusion criteria); interventions (e.g., characteristic, frequency of use, duration of use), comparisons and the outcome results. &lt;/p&gt;&#xD;&#xA;&lt;p&gt;For continuous outcomes, they extracted the mean difference between groups and a measure of dispersion. For dichotomous outcomes, they extracted the number of events and the number of participants in each group. &lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Quality Evaluation&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Quality Evaluation of Existing Systematic Reviews &lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Two independent reviewers assessed the quality of existing systematic reviews. They assessed the quality of existing systematic reviews using the Revised Assessment of Multiple Systematic Reviews (R-AMSTAR). It could produce quantifiable assessments of systematic review quality. &lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Risk of Bias Assessment of Individual Studies &lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;They evaluated the risk of bias in individual randomized controlled trials (RCTs) using the Cochrane risk of bias (RoB) tool. &lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Data Synthesis&lt;/span&gt;&lt;/strong&gt; &lt;/p&gt;&#xD;&#xA;&lt;p&gt;Data synthesis was conducted in the development of new systematic reviews. The guideline development group conducted meta-analyses when there were sufficient data (at least 2 trials) and studies were sufficiently homogeneous. They tested the heterogeneity among the trials considered for quantitative pooling using a chi-squared test with a significance level of alpha less than or equal to 0.05, and also examined heterogeneity among studies with an &lt;em&gt;I&lt;/em&gt;&amp;sup2; statistic. They pooled the mean difference/risk ratio between groups using a random-effects model with the low heterogeneity (&lt;em&gt;I&lt;/em&gt;&amp;sup2;&amp;lt;50%) or fixed-effects model with no heterogeneity.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Strength of the Body of Evidence&lt;/span&gt;&lt;/strong&gt; &lt;/p&gt;&#xD;&#xA;&lt;p&gt;The newly developed systematic reviews and existing systematic reviews of high quality (Score of R-AMSTAR &amp;ge;70) were used as the evidence for key clinical questions. After the completion of the newly developed systematic reviews, the guideline development group assessed the strength of the body of evidence using the GRADE approach. &lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="112" OrdBy="540" ID="413" Name="Methods Used to Formulate the Recommendations" Type="picklist-choice">
      <FieldValue Value="Expert Consensus (Delphi)" />
    </Field>
    <Field FieldID="145" OrdBy="545" ID="414" Name="Description of Methods Used to Formulate the Recommendations" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Going from Evidence to Recommendation&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;According to the GRADE approach, the guideline development group adopted the GRADE grid and used a modified Delphi technique to develop the grade of recommendation. In this process, they considered the patient value and preference, economic factors, benefits and harms and quality of evidence together.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Patient Value and Preference&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The guideline development group conducted a survey to acquire the information about patient values and preferences.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Economic Factors &lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The guideline development group considered the economic factors from the cost of non-pharmaceutical therapies and cost of Chinese patent medicine. &lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Consensus Rules&lt;/strong&gt; &lt;/p&gt;&#xD;&#xA;&lt;p&gt;Here are some rules about the consensus:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Except &quot;0&quot;, the vote of any choices is more than 50%, which is deemed to reach a consensus. The guideline development group can make a decision about the direction and strength of the recommendation. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The vote of any two choices (happened simultaneously at the right of &quot;0&quot; or the left of &quot;0&quot;) is more than 70%, which is deemed to reach a consensus. The guideline development group can make a decision about the direction of the recommendation, and the strength of the recommendation is &quot;weak&quot;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;And, the other situations are not deemed to reach a consensus. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Result - Going from Evidence to Recommendation&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Patient Values and Preferences&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;A total of 217 subjects took part in their investigation of patient values and preferences. There were 72 men and 145 women, aged from 18 to 72 years. The results are as follows: &lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;When patients chose the treatment for primary headache disorders, first, they would consider the cure, reducing recurrence, low incidence of adverse reactions, and then, the convenience of treatment and rapid pain relief and, last, the treatment cost and health insurance. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;When patients chose the treatment for primary headache disorders, they would choose non-pharmaceutical therapy, and then the pharmaceutical therapy. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;When patients chose non-pharmaceutical therapy, they would choose acupuncture and tuina, and then other non-pharmaceutical therapies. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;When patients chose pharmaceutical therapy, they would choose Chinese patent medicine, and then Western medicine. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Recommendation Consensus &lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;A total of 21 experts (see Table 1 in the Appendix [see the &quot;Availability of Companion Documents&quot; field]) took part in the consensus conference. On the basis of quality of evidence, benefits and harms, patient value and preference and economic factors, the guideline development group conducted a 3 rounds consensus and developed 15 recommendations. Consensus results of each round are presented in Table 2, Table 3 and Table 4 in the Appendix.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="146" OrdBy="550" ID="415" Name="Rating Scheme for the Strength of the Recommendations" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Strength of Recommendation&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;1&quot; cellpadding=&quot;3&quot; summary=&quot;Table: Strength of Recommendation&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot; scope=&quot;col&quot;&gt;Recommendation&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot; scope=&quot;col&quot;&gt;Benefits and Risks&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Strong &quot;Must do&quot;&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Benefits clearly outweigh risks&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Weak &quot;Might do&quot;&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Benefits might outweigh risks&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;No clear recommendation&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Benefits are equal to risks OR uncertain&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Weak &quot;Might do&quot;&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Risk might outweigh benefits&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Weak &quot;Must not do&quot;&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Risks clearly outweigh benefits&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="148" OrdBy="565" ID="417" Name="Cost Analysis" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;A formal cost analysis was not performed and published cost analyses were not reviewed.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="104" OrdBy="570" ID="418" Name="Method of Guideline Validation" Type="picklist-choice">
      <FieldValue Value="External Peer Review" />
      <FieldValue Value="Internal Peer Review" />
    </Field>
    <Field FieldID="130" OrdBy="575" ID="419" Name="Description of Method of Guideline Validation" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The guideline was reviewed using the Appraisal of Guidelines for Research and Evaluation II (AGREE II) as the evaluation tool (Scope and purpose: 79%, Stakeholder involvement: 78%, Rigour of development: 78%, Clarity of presentation: 71%, Applicability: 70%, Editorial independence: 81%). The reviewers consist of a multidisciplinary group of individuals (including doctors of Traditional Chinese Medicine, nurses, methodologist, etc.). The guideline was adjusted by consensus of these reviewers and approved by the China Association of Chinese Medicine.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
  </Section>
  <Section SecID="424" OrdBy="600" Name="Evidence Supporting the Recommendations">
    <Field FieldID="139" OrdBy="610" ID="426" Name="Type of Evidence Supporting the Recommendations" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The type of supporting evidence is identified and graded for each recommendation (see the &quot;Major Recommendations&quot; field).&lt;/p&gt;&lt;/div&gt;" />
    </Field>
  </Section>
  <Section SecID="427" OrdBy="700" Name="Benefits/Harms of Implementing the Guideline Recommendations">
    <Field FieldID="152" OrdBy="705" ID="428" Name="Potential Benefits" Type="text">
      <FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;A priority aim and benefit of implementing the recommendations in this guideline would be to improve the percentage of individuals who are able to meet their treatment goal of improving the headache condition. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The guideline provides therapies for primary headache disorders on the basis of systematic reviews. It gives more alternative options for doctors/patients to choose the suitable treatment. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Traditional Chinese Medicine therapy has good safety. Clinical studies have not reported serious adverse reactions. Traditional Chinese Medicine therapy can reduce the drug dependence in the long-term use. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The guideline would guide and standardize clinical rational use of Traditional Chinese Medicine and reduce excessive differences in the use of Traditional Chinese Medicine for primary headache disorders. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" />
    </Field>
    <Field FieldID="153" OrdBy="710" ID="429" Name="Potential Harms" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Traditional Chinese Medicine, especially acupuncture and tuina, need professionals to handle.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
  </Section>
  <Section SecID="432" OrdBy="900" Name="Qualifying Statements">
    <Field FieldID="137" OrdBy="905" ID="433" Name="Qualifying Statements" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Clinical practice guidelines are developed to be of assistance to physicians, who want to use Traditional Chinese Medicine in the treatment of primary headache disorders, by providing guidance and recommendations. The guidelines are not intended to dictate the treatment of a particular patient. Treatment decisions must be made based on the independent judgment of physicians and each patient's individual circumstances.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
  </Section>
  <Section SecID="434" OrdBy="1000" Name="Implementation of the Guideline">
    <Field FieldID="131" OrdBy="1010" ID="436" Name="Description of Implementation Strategy" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The guideline will be published by the China Association of Chinese Medicine. The Guangdong Provincial Hospital of Chinese Medicine will spread it through training and academic communication. They will promote the diffusion by developing the guideline into Chinese and English. &lt;/p&gt;&#xD;&#xA;&lt;p&gt;The Guangdong Provincial Hospital of Chinese Medicine will check the implementation of the guideline and update the guideline according to the feedback.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
  </Section>
  <Section SecID="439" OrdBy="1100" Name="Institute of Medicine (IOM) National Healthcare Quality Report Categories">
    <Field FieldID="50" OrdBy="1105" ID="440" Name="IOM Care Need" Type="picklist-many">
      <FieldValue Value="Getting Better" />
    </Field>
    <Field FieldID="51" OrdBy="1110" ID="441" Name="IOM Domain" Type="picklist-many">
      <FieldValue Value="Effectiveness" />
    </Field>
  </Section>
  <Section SecID="442" OrdBy="1200" Name="Identifying Information and Availability">
    <Field FieldID="97" OrdBy="1201" ID="392" Name="Bibliographic Source(s)" Type="citation">
      <FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Guangdong Provincial Hospital of Chinese Medicine. Traditional Chinese medicine treatment guideline for primary headache disorders. Guangdong Sheng (China): Guangdong Provincial Hospital of Chinese Medicine; 2018 Jan 30. 5 p.  [44 references]&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" />
    </Field>
    <Field FieldID="124" OrdBy="1205" ID="443" Name="Adaptation" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not applicable: The guideline is not adapted from another source.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="128" OrdBy="1215" ID="445" Name="Date Released" Type="text">
      <FieldValue Value="2018 Jan 30" />
    </Field>
    <Field FieldID="158" OrdBy="1225" ID="447" Name="Guideline Developer(s)" Type="orglist-p">
      <FieldValue Value="Guangdong Provincial Hospital of Chinese Medicine - Hospital/Medical Center" />
    </Field>
    <Field FieldID="125" OrdBy="1235" ID="449" Name="Source(s) of Funding" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This research was funded by State Administration of Traditional Chinese Medicine (Standardization project, No. SATCM-2015-183).&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="126" OrdBy="1240" ID="450" Name="Guideline Committee" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Guideline Development Group&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="127" OrdBy="1245" ID="451" Name="Composition of Group That Authored the Guideline" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;em&gt;Guideline Development Group Members&lt;/em&gt;: Dr. Hui Li, Guangdong Provincial Hospital of Chinese Medicine; Pro. Yan Huang, Guangdong Provincial Hospital of Chinese Medicine; Dr. Yaolong Chen, Lanzhou University; Pro. Xinfu Lian, Guangdong Provincial Hospital of Chinese Medicine; Pro. Yanmei Li, The first affiliated hospital of Henan University of Traditional Chinese Medicine (TCM); Dr. Xingchen Wang, The second affiliated hospital of Shandong University of TCM; Pro. Qingbo Ju, The affiliated hospital of Liaoning University of TCM; Dr. Cunzhi Liu, Beijing Hospital of TCM; Pro. Guoqing Lin, Fujian Provincial People's Hospital; Pro. Yong Zhao, Nanhai Maternity and Child Healthcare Hospital of Foshan Guangdong; Pro. Yuntian Wu, Shenzhen Hospital of Guangzhou University of TCM; Dr. Ning Tian, Guangdong Provincial Hospital of Integrated Chinese and Western Medicine; Pro. Lina He, Community healthcare center of Guangta Street; Yangyang Wang, MPH, Guangdong Provincial Hospital of Chinese Medicine&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="147" OrdBy="1250" ID="452" Name="Financial Disclosures/Conflicts of Interest" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;In the interest of full disclosure, the Guangdong Provincial Hospital of Chinese Medicine has adopted the policy of revealing relationships workgroup members have with companies that sell products or services that are relevant to this topic. Workgroup members are required to disclose potential conflicts of interest by completing the Conflict of Interest Form. Further details may be requested by contacting &lt;a href=&quot;mailto:lihuitcm@126.com&quot;&gt;lihuitcm@126.com&lt;/a&gt;. It should not be assumed that these financial interests will have an adverse impact on the content, but they are noted in the original guideline document to fully inform readers. &lt;/p&gt;&#xD;&#xA;&lt;p&gt;Hui Li received a grant from the state administration of Traditional Chinese Medicine.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="120" OrdBy="1256" ID="393" Name="Guideline Status" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;This guideline meets NGC's 2013 (revised) inclusion criteria.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="118" OrdBy="1260" ID="454" Name="Guideline Availability" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Available from the &lt;a href=&quot;http://120.25.192.163/Contents/Item/Display/5607&quot; title=&quot;Guangdong Provincial Hospital of Chinese Medicine Web site&quot;&gt;Guangdong Provincial Hospital of Chinese Medicine Web site&lt;/a&gt;.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="119" OrdBy="1265" ID="455" Name="Availability of Companion Documents" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The following is available:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Guangdong Provincial Hospital of Chinese Medicine. Traditional Chinese medicine treatment guideline for primary headache disorders. Appendix. Guangdong Sheng (China): Guangdong Provincial Hospital of Chinese Medicine; 2018 Jan 30. 54 p. Available from the &lt;a href=&quot;http://120.25.192.163/Media/Default/Users/çæ´æ´/Appendix/Appendix.docx&quot; title=&quot;Guangdong Provincial Hospital of Chinese Medicine Web site&quot;&gt;Guangdong Provincial Hospital of Chinese Medicine Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="143" OrdBy="1275" ID="457" Name="Patient Resources" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None available&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="142" OrdBy="1280" ID="458" Name="NGC Status" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary was completed by ECRI Institute on April 23, 2018. The information was verified by the guideline developer on May 9, 2018. &lt;/p&gt;&#xD;&#xA;&lt;p&gt;This NEATS assessment was completed by ECRI Institute on April 17, 2018. The information was verified by the guideline developer on May 9, 2018. &lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="141" OrdBy="1290" ID="460" Name="Copyright Statement" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;This guideline is a clinical reference for clinicians, and clinical treatment decisions should be made according to clinical situation and patient preference.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;This guideline is strictly prohibited for commercial purposes without authorization.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;When you use this guideline for purposes of research, education or other non-commercial use, please indicate provenance. &lt;/p&gt;&lt;/div&gt;" />
    </Field>
  </Section>
  <Section SecID="99999" OrdBy="99999" Name="Disclaimer">
    <Field FieldID="99999" OrdBy="99999" ID="99999" Name="NGC Disclaimer" Type="text">
      <FieldValue Value="&lt;p&gt;The National Guideline Clearinghouseâ¢ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the &lt;a href=&quot;/help-and-about/summaries/inclusion-criteria&quot;&gt;NGC Inclusion Criteria&lt;/a&gt;.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Readers with questions regarding guideline content are directed to contact the guideline developer.&lt;/p&gt;" />
    </Field>
  </Section>
</Version>